Table 4.
Trial 1 | Trial 2 | Trial 3 | ICC (2vs3) |
p-value (ICC) |
p-value (ANOVA or Friedman) * |
|
---|---|---|---|---|---|---|
IHP | ||||||
BBT-VR-C | 17 ± 8.6 | 18 ± 11.1 | 20 ± 11.8 | 0.96 | < 0.001 | 0.005 |
BBT-VR-HT | 20 ± 12.5 | 23 ± 15.5 | 25 ± 17.0 | 0.96 | < 0.001 | 0.001 |
MD-MR | 19 ± 10.3 | 20 ± 9.8 | 21 ± 10.3 | 0.99 | < 0.001 | 0.007 |
HCP | ||||||
BBT-VR-C | 46 ± 15.9 | 54 ± 17.1 | 60 ± 16.2 | 0.92 | < 0.001 | < 0.001 |
BBT-VR-HT | 52 ± 19.8 | 60 ± 21.8 | 60 ± 19.8 | 0.86 | < 0.001 | 0.005 |
MD-MR | 42 [39–45.5] | 43 [42–47.5] | 46 [42.5–48.5] | 0.76 | < 0.001 | 0.072 |
ICC = Intraclass Correlation Coefficient; *Bonferroni adjustments applied for ANOVA post-hoc tests and Tukey adjustments applied for Friedman ANOVA pairwise comparisons; IHP = Individuals with stroke suffering from hemiparesis; HCP = Healthy control participants